TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved Emcitate (tiratricol) for peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The agency says studies found lower excess thyroid hormone levels and improvements in some cardiovascular and metabolic measures; the approval does not establish that the medicine reverses the condition’s neurological effects.
The U.S. Food and Drug Administration on September 28 approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare genetic disorder also known as Allan-Herndon-Dudley syndrome. The FDA said it is the first therapy it has approved to treat symptoms of the condition, which can leave patients with too little thyroid hormone reaching the brain while excess hormone builds up in the bloodstream.
The approval covers peripheral thyrotoxicosis, meaning excess thyroid hormone levels in the blood that cause symptoms and affect the body outside the brain. The FDA lists possible effects including rapid heart rate, elevated blood pressure and changes to metabolism. The agency’s announcement describes Emcitate as a way to lower the elevated hormone levels; it does not say that the medicine corrects the faulty gene or restores normal thyroid hormone delivery to the brain.
The FDA evaluated effectiveness in two studies involving patients from infancy through adulthood: an international, multicenter randomized, placebo-controlled trial and a longer-term open-label study. Across both studies, the agency reported reductions in excess thyroid hormone in the bloodstream and improvements in cardiovascular and metabolic symptoms affected by thyroid levels, including systolic blood pressure and heart rate. The release does not provide the size of those changes or a detailed breakdown of outcomes by age group.
Emcitate is taken once daily as a liquid suspension, by mouth or through a feeding tube for people who have difficulty swallowing. The FDA lists diarrhea, vomiting, rash and excessive sweating as the most common side effects. It also says patients taking another thyroid medication should speak with their health care provider before starting Emcitate because the medicines should not be used together. The approval was granted to Egetis Therapeutics US Inc.
A New Option for Thyroid Effects
For patients and families, the approval adds an FDA-authorized treatment for one part of a rare condition that the agency says previously had no approved treatment option. The target is excess thyroid hormone in the bloodstream and related cardiovascular and metabolic effects. Reducing that excess may address a source of strain on the body in people with MCT8 deficiency.
The condition can also involve substantial neurological and developmental needs. The FDA says many patients have difficulty sitting or walking independently, absent or severely limited speech, intellectual disability and feeding difficulties. The reported study findings concern hormone levels and certain cardiovascular and metabolic measures; the agency release does not report that Emcitate improves speech, mobility, intellectual disability or other neurological effects. Families and clinicians will need to distinguish the approved treatment goal from the broader effects of the disorder.
The formulation may be practical for patients with different swallowing abilities because it can be given through a feeding tube. At the same time, the listed side effects and the restriction on combining it with another thyroid medication are relevant to treatment decisions. Prescribing and monitoring will need to take account of each patient’s health, current medicines and ability to tolerate the suspension.
How MCT8 Disrupts Hormone Delivery
MCT8 deficiency is caused by a faulty gene that provides instructions for making the MCT8 transporter, a protein involved in carrying thyroid hormone into the brain. According to the FDA, without a functioning transporter, thyroid hormone cannot cross the blood-brain barrier normally. This leaves the brain with too little of the hormone while excess levels accumulate in the bloodstream.
That split helps explain why the condition can affect the brain as well as the heart and metabolism. The FDA describes a range of serious effects, including limited independent movement, speech impairment, intellectual disability, feeding difficulties and chronic stress on the heart and metabolism. The condition primarily affects males, the agency said.
FDA officials said tiratricol can enter cells without depending on the faulty MCT8 transporter. Deputy director Marina Zemskova said patients and families had lacked an FDA-approved treatment option. Hylton V. Joffe, director of the FDA office overseeing the review, described the drug as sidestepping the transporter problem and said it lowers elevated blood thyroid hormone levels. The agency granted the application Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations, as well as Priority Review. Those designations describe the review and development pathway; they do not by themselves establish the size of a treatment benefit.
““This drug sidesteps that problem.””
— Hylton V. Joffe, director of the FDA’s Office of Cardiology, Hematology, Endocrinology, and Nephrology
Limits of the Reported Findings
The FDA announcement does not give numerical results for the hormone reductions or changes in blood pressure and heart rate. It also does not specify how those outcomes varied across the infant-to-adult age range, how long benefits persisted for individual patients, or how the reported changes affected daily functioning. The agency said one study was open-label, but the release does not provide further detail on its design or duration.
It remains unclear from the announcement whether treatment changes neurological or developmental effects, or how it may affect longer-term outcomes such as mobility, communication, feeding and heart health. The approval statement focuses on peripheral thyrotoxicosis; it should not be read as evidence that the underlying genetic disorder or all of its effects are corrected. The FDA release also does not give a detailed account of risks beyond the most common side effects it names.
Treatment Decisions and Follow-Up
Patients and caregivers can discuss the approval with the health care professionals managing MCT8 deficiency, including whether Emcitate fits the patient’s symptoms and current treatment. The FDA specifically advises that people taking another thyroid medication speak with their provider before starting, since the medicines should not be used together. Clinicians will need to consider the patient’s medication list and monitor for side effects such as diarrhea, vomiting, rash or excessive sweating.
Further information from the manufacturer or additional reporting on the clinical studies may clarify the size and durability of the measured changes, outcomes across age groups and longer-term experience with treatment. For now, the confirmed development is an FDA approval to treat excess thyroid hormone and related peripheral symptoms in MCT8 deficiency; the extent of any effect on the condition’s neurological features remains unreported in the FDA announcement.
Key Questions
What did the FDA approve?
The FDA approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome.
What did the studies find?
The FDA said two studies found lower excess thyroid hormone levels in the bloodstream and improvements in some cardiovascular and metabolic measures, including systolic blood pressure and heart rate. Its announcement does not give numerical effect sizes.
Does the approval mean the treatment reverses neurological effects?
The FDA announcement does not report that Emcitate reverses neurological or developmental effects such as speech impairment, intellectual disability or limited mobility. Its stated use is to treat peripheral thyrotoxicosis.
How is Emcitate taken, and what side effects were reported?
It is taken once daily as a liquid suspension, by mouth or through a feeding tube. The FDA lists diarrhea, vomiting, rash and excessive sweating as the most common side effects.
Can it be taken with another thyroid medication?
The FDA says patients taking another thyroid medication should speak with their health care provider before starting Emcitate because the two should not be used together.
Source: primary
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
